Encapsulates paclitaxel (PTX), a widely used chemotherapeutic agent, within a nanoparticle designed to enhance drug delivery and tumor accumulation.

Manufactured through a proprietary 16-step nanoprocess, producing biocompatible and biodegradable nanoparticles.

Designed to minimize nonspecific exposure of paclitaxel in the bloodstream and to normal cells.

Demonstrated outstanding safety and high tolerability across extensive preclinical studies.

Established high No Observed Adverse Effect Levels (NOAELs) in completed preclinical toxicology studies, with no treatment-related adverse effects observed at those dose levels.

No treatment-related adverse events were observed in completed preclinical studies.

Demonstrated significantly greater tumor reduction than Abraxane and the highest level of cancer cell death in a preclinical pancreatic cancer model.

Water-dispersible formulation that forms an aqueous suspension, with a nanoparticle size of less than 100 nm—approximately one-thousandth the width of a human hair.
※ A nanometer is one billionth of a meter (10⁻⁹ m).